Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)

Tuesday, November 21, 2017 2:01 PM UTC

DEVON, Pa., Nov. 21, 2017 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced the acceptance and presentation details of a Late Breaking poster at the 2017 Annual Meeting of the American Epilepsy Society (AES) in Washington, DC, taking place December 1 through December 5, 2017.

Sunday, December 3, 2017
Poster title: “Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults”
Poster session: 2
Poster number: 428
Author presentation time: 12:00PM – 2:00PM EST
Display time: 10:00AM – 4:00PM EST
Location: Hall B, Lower Level
Abstract ID: 2.428

About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is dedicated to improving the lives of people with severe health conditions where there is a high unmet medical need by developing and commercializing pharmaceutically-produced transdermal cannabinoid medicines designed to meet the rigorous efficacy and safety standards established by global regulatory agencies. Through the discovery and development of these life-changing medicines, Zynerba seeks to improve the lives of patients battling severe, chronic health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Learn more at www.zynerba.com and follow the Company on Twitter at @ZynerbaPharma.

Zynerba Contact
Will Roberts, VP Investor Relations and Corporate Communications
484.581.7489
[email protected]

Media contact
Theresa Dolge
Tonic Life Communications
Office: 215-928-2748
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)

Editor's Picks

Welcome to EconoTimes